Sunday, December 3, 2023
Medical Learning Institute, Inc, is committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education. To that end, MLI requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to MLI policy. These disclosures will be provided to learners prior to the start of the CE activity.
Associate Professor
Department of Leukemia
Division of Cancer Medicine
University of Texas
MD Anderson Cancer Center
Houston, Texas
Professor of Medicine
Director, Leukemia Program
Duke University
Durham, North Carolina
Associate Professor of Medicine
Leader, Myeloid Diseases and Leukemia Aligned Research Team
Yale Cancer Center
Yale University School of Medicine
New Haven, Connecticut
All of the relevant financial relationships of individuals for this activity have been mitigated.
The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, and Medscape Education, the educational partner, do not have any relevant financial relationship(s) to disclose with ineligible companies.
Physicians - maximum of 0.75 AMA PRA Category 1 Credit(s)™
Nurses - 0.75 ANCC Contact Hour(s) (0.75 contact hours are in the area of pharmacology)
Pharmacists - 0.75 Knowledge-based ACPE (0.075 CEUs)
This activity is intended for hematology/oncology specialists, nurses, pharmacists, and other healthcare professionals involved in the care of patients with AML.
The goal of this activity is for learners to be better able to interpret the latest data on novel approaches to the treatment of AML and to understand the potential impact on the AML therapy landscape.
Upon completion of this activity, participants will:
Medical Learning Institute, Inc, is committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education. To that end, MLI requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to MLI policy. These disclosures will be provided to learners prior to the start of the CE activity.
Associate Professor
Department of Leukemia
Division of Cancer Medicine
University of Texas
MD Anderson Cancer Center
Houston, Texas
Professor of Medicine
Director, Leukemia Program
Duke University
Durham, North Carolina
Associate Professor of Medicine
Leader, Myeloid Diseases and Leukemia Aligned Research Team
Yale Cancer Center
Yale University School of Medicine
New Haven, Connecticut
All of the relevant financial relationships of individuals for this activity have been mitigated.
The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, and Medscape Education, the educational partner, do not have any relevant financial relationship(s) to disclose with ineligible companies.
This activity is developed with our educational partner, Medscape Oncology.
Medical Learning Institute, Inc. (MLI) designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this nursing continuing professional development activity will be awarded 0.75 contact hour and 0.75 contact hour in the area of pharmacology.
Medical Learning Institute, Inc. designates this continuing education activity for 0.75 contact hour (0.075 CEU) of the Accreditation Council for Pharmacy Education. UAN: JA0007322-0000-23-082-H01-P. Activity Type: Knowledge.
MLI will accept your completed evaluation form for up to 30 days post-activity and will report your participation to the NABP only if you provide your NABP e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your participation record at the NABP website: https://nabp.pharmacy/.
For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]
There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.
This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.
Follow these steps to earn CME/CPD/NCPD credit*:
You may now view or print the certificate from your CME/CPD/NCPD Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CPD/NCPD Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CPD/NCPD Tracker.
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
CME / CE Released: 9/29/2023
Valid for credit through: 9/29/2024, 11:59 PM EST
processing....
Please answer the questions below to self-assess your knowledge. Answering these questions again after the activity will allow you to see what you learned.
